JPH01125328A - 髄膜炎菌ワクチン - Google Patents

髄膜炎菌ワクチン

Info

Publication number
JPH01125328A
JPH01125328A JP63190500A JP19050088A JPH01125328A JP H01125328 A JPH01125328 A JP H01125328A JP 63190500 A JP63190500 A JP 63190500A JP 19050088 A JP19050088 A JP 19050088A JP H01125328 A JPH01125328 A JP H01125328A
Authority
JP
Japan
Prior art keywords
protein
treatment
chromatography
meningococcus
molecular weight
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP63190500A
Other languages
English (en)
Inventor
Concepcion C Huergo
コンセプシオン　カムパ　フェルゴ
Gonzalez Victoriano G Sierra
ビクトリアーノ　グスタボ　シエラ　ゴンザレツ
Vazquez Maria M Gutierrez
マリア　メルセデス　グティエレツ　バズクエズ
Jorrin Gonzalo Bisset
ゴンザロ　ビセット　ジョリン
Imia Luis G Garcia
ルイス　グイレルモ　ガルシア　イミア
La Caridad Puentes Rizo Gis De
ギセラ　デ　ラ　カリダッド　プエンテス　リゾ
Carmen Sampedro Herrera Ma Del
マリア　デル　カルメン　サムペドロ　ヘレラ
Padron Franklin Sotolongo
フランクリン　ソトロンゴ　パッドロン
Riverend Morales Eloisa X Le
エロイサ　ソチツル　レ　リベレンド　モラレス
Dominguez Manuel A Galguera
マヌエル　アルフレド　ガルグエラ　ドミンゲツ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CENTRO NATL DE BIOPREPARADOS
Original Assignee
CENTRO NATL DE BIOPREPARADOS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CENTRO NATL DE BIOPREPARADOS filed Critical CENTRO NATL DE BIOPREPARADOS
Publication of JPH01125328A publication Critical patent/JPH01125328A/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1217—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Neisseriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Abstract

(57)【要約】本公報は電子出願前の出願データであるた
め要約のデータは記録されません。

Description

【発明の詳細な説明】 本発明は、Ｂ型髄膜炎菌（ナイセリアメニンギチジス）
の任意の既知病原性血清型の生菌に出発することを特徴
とするＢ型髄膜炎菌の各種病原性血清型に対するワクチ
ンを製造する方法に関する。
すなわち、Ｂ型髄膜炎菌の任意の既知病原性血清型の生
菌に、不活化することなく、界面活性剤処理、酵素処理
および超音波処理の組合せを適用して外膜のベジクルお
よび分子量６５〜９５ＫＤの蛋白質抗原性複合体を抽出
し、得られた生成物に核酸除去操作を施したのち、界面
活性剤、超音波浴およびカラムクロマトグラフィーによ
る解離処理を行い、得られた多重抗原物質を、１−ＩＰ
ＬＣクロマトグラフィー（ＴＳＫ　　３００　　ＳＷＧ
　　カラム）、モノクローナル抗体によるアフイニテイ
クロマトグラフイー、疎水性クロマトグラフィーもしく
はイオン交換クロマトグラフィー、またはそれらの組合
せによって精製して分子量６５〜９５ＫＤの蛋白質抗原
性複合体を得、この蛋白質抗原性複合体を、ベジクルを
含有する分画に１５％の割合で３回添加して超音波処理
してベジクル上に撃留させ、さらに莢膜多糖を蛋白質に
対して１．１〜１．４の割合で、またアジュバントを２
０〜１００μグ／μｇ蛋白質の割合で加え、混合物中の
各種成分は混合物の調整前に温度１〜４℃においでコバ
ルト６０による円部５〜２５ＫＧＹのイオン化照射を行
って滅菌するか、または同じ操作で混合物の調整後に滅
菌することにより、Ｂ型髄膜炎菌の各種病原性血清型に
対するワクチンを製造する。
本発明はまた、Ｂ型髄膜炎菌の各種病原性血清型に対し
、広領域かつ持続性の防御効果を示すワクチンに関する
。このワクチンは、各種の既知病原性血清型の存在と共
通する抗原性を付与し、殺菌性抗体の生成を誘導する、
分子量６５〜９５ＫＤの上記蛋白質抗原性複合体の免疫
学的有効量；抗原性血清型決定基およびエンドトキシン
に対する特異的抗体の強力な応答を誘導するのに必要な
割合のベジクル；全体の溶解性および免疫原性を増大さ
せ、また、２歳未満の乳幼児においてさえも、多糖成分
に対する応答を増大させてその多価性を付与するのに必
要な割合の莢膜多糖：ならびにその効果を至適化するの
に必要な最のアジュバントを含有する。
本発明はまた、Ｂ型髄膜炎菌の各種病原性血清型の任意
の菌に対して殺菌および中和活性を有し、それによって
惹起される髄膜炎および髄膜炎菌血症の予防および治療
に広領域に有効な抗髄膜炎菌超免疫ガンマグロブリンに
関する。
さらに本発明は、８型髄膜炎菌に対するＴｉｌ［ｌ胞免
疫を運搬するために使用される特異的１〜ランスフアー
因子（白血球抽出物から透析できる）に関する。

Claims (4)

    【特許請求の範囲】
  1. （１）Ｂ型髄膜炎菌の任意の既知病原性血清型の生菌に
    、不活化することなく、界面活性剤処理、酵素処理およ
    び超音波処理の組合せを適用して外膜のベジクルおよび
    分子量６５〜９５ＫＤの蛋白質抗原性複合体を抽出し、
    得られた生成物に核酸除去操作を施したのち、界面活性
    剤、超音波浴およびカラムクロマトグラフィーによる解
    離処理を行い、得られた多重抗原物質を、ＨＰＬＣクロ
    マトグラフィー、モノクローナル抗体によるアフイニテ
    ィークロマトグラフィー、疎水性クロマトグラフィーも
    しくはイオン交換クロマトグラフィーまたはそれらの組
    合せによつて精製して分子量６５〜９５ＫＤの蛋白質抗
    原性複合体を得、この蛋白質抗原性複合体を、ベジクル
    を含有する分画に１５％の割合で３回添加し、超音波処
    理してベジクル上に繋留させ、さらに莢膜多糖を蛋白質
    に対して１．１〜１．４の割合で、またアジユバントを
    ２０〜１００μｇ／μｇ蛋白質の割合で加え、混合物中
    の各種成分を混合物の調整前に滅菌しておくかまたは混
    合物の調整後に滅菌を行うことを特徴とするＢ型髄膜炎
    菌の各種病原性血清型に対するワクチンの製造方法
  2. （２）Ｂ型髄膜炎菌の任意の既知病原性血清型の存在と
    共通の抗原性を付与し、殺菌性抗体の生成を誘導する、
    分子量６５〜９５ＫＤの蛋白質抗原性複合体の免疫学的
    有効量：抗原性血清型決定基およびエンドトキシンに対
    する特異的抗体の応答を誘導するのに必要な割合のベジ
    クル；全体の溶解性および免疫原性を増大させ、また多
    糖成分に対する応答を増大させて多価性を付与するのに
    必要な割合の莢膜多糖；ならびに効果を至適化するのに
    必要な量のアジユバントを含有することを特徴とするＢ
    型髄膜炎菌の各種病原性血清型に対するワクチン
  3. （３）Ｂ型髄膜炎菌の各種病原性血清型に対して殺菌お
    よび中和活性を有する抗髄膜炎菌超免疫ガンマグロブリ
    ン
  4. （４）Ｂ型髄膜炎菌に対するＴ細胞免疫を運搬する特異
    的トランスファー因子
JP63190500A 1987-07-30 1988-07-29 髄膜炎菌ワクチン Pending JPH01125328A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CU125/87 1987-07-30
CU1987125 1987-07-30

Publications (1)

Publication Number Publication Date
JPH01125328A true JPH01125328A (ja) 1989-05-17

Family

ID=5459411

Family Applications (1)

Application Number Title Priority Date Filing Date
JP63190500A Pending JPH01125328A (ja) 1987-07-30 1988-07-29 髄膜炎菌ワクチン

Country Status (11)

Country Link
US (2) US5597572A (ja)
EP (1) EP0301992B1 (ja)
JP (1) JPH01125328A (ja)
AT (1) ATE122893T1 (ja)
AU (3) AU615461B2 (ja)
CA (1) CA1341199C (ja)
DE (1) DE3853854T2 (ja)
ES (1) ES2074445T3 (ja)
GR (1) GR3017218T3 (ja)
IN (1) IN167607B (ja)
RU (1) RU2023448C1 (ja)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2070312T5 (es) * 1988-12-19 2003-05-16 American Cyanamid Co Vacuna de proteina de membrana exterior meningococica de clase 1.
US7118757B1 (en) 1988-12-19 2006-10-10 Wyeth Holdings Corporation Meningococcal class 1 outer-membrane protein vaccine
CU22302A1 (es) * 1990-09-07 1995-01-31 Cigb Secuencia nucleotidica codificante para una proteina de la membrana externa de neisseria meningitidis y uso de dicha proteina en preparados vacunales
DE69423383T2 (de) * 1993-05-13 2000-08-24 American Cyanamid Co Herstellung und Verwendungen von LOS-verminderten Aussenmembran-Proteinen von Gram-negativen Kokken
US6287574B1 (en) 1995-03-17 2001-09-11 Biochem Pharma Inc. Proteinase K resistant surface protein of neisseria meningitidis
DK0854729T3 (da) * 1995-09-18 2004-07-12 Id Biomedical Corp Quebec Forbedrede fremgangsmåder til fremstillingen af ikke-kovalent kompleksdannede og multivalente proteosom-subunit-vacciner
FR2751000B1 (fr) 1996-07-12 1998-10-30 Inst Nat Sante Rech Med Adn specifiques des bacteries de l'espece neisseria meningitidis, leurs procedes d'obtention et leurs applications biologiques
US6558677B2 (en) * 1996-10-15 2003-05-06 Wendell D. Zollinger Vaccine against gram negative bacteria
GB9726398D0 (en) 1997-12-12 1998-02-11 Isis Innovation Polypeptide and coding sequences
GB9808734D0 (en) * 1998-04-23 1998-06-24 Smithkline Beecham Biolog Novel compounds
GB9808866D0 (en) * 1998-04-24 1998-06-24 Smithkline Beecham Biolog Novel compounds
GB9810276D0 (en) * 1998-05-13 1998-07-15 Smithkline Beecham Biolog Novel compounds
GB9811260D0 (en) * 1998-05-26 1998-07-22 Smithkline Beecham Biolog Novel compounds
US10967045B2 (en) 1998-11-02 2021-04-06 Secretary of State for Health and Social Care Multicomponent meningococcal vaccine
GB9823978D0 (en) 1998-11-02 1998-12-30 Microbiological Res Authority Multicomponent meningococcal vaccine
WO2000043517A1 (en) * 1999-01-22 2000-07-27 Smithkline Beecham Biologicals S.A. Basb055 polynucleotide and polypeptide from neisseria meningitidis. uses thereof
CA2929348A1 (en) 1999-05-19 2000-11-30 Novartis Vaccines And Diagnostics S.R.L. Combination neisserial compositions
GB9918319D0 (en) 1999-08-03 1999-10-06 Smithkline Beecham Biolog Vaccine composition
GB9929923D0 (en) * 1999-12-17 2000-02-09 Baldwin Thomas J Antigen preparations
AU2001280883A1 (en) * 2000-07-27 2002-02-13 The Children's Hospital & Research Center At Oakland Vaccines for broad spectrum protection against diseases caused by neisseria meningitidis
GB0103170D0 (en) 2001-02-08 2001-03-28 Smithkline Beecham Biolog Vaccine composition
GB0103171D0 (en) 2001-02-08 2001-03-28 Smithkline Beecham Biolog Vaccine composition
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
IL145926A0 (en) 2001-10-15 2002-07-25 Mor Research Applic Ltd Peptide epitopes of mimotopes useful in immunomodulation
CU22983A1 (es) * 2002-05-08 2004-09-09 Inst Finlay Composición vacunal contra las alergias y método para su obtención y empleo en el tratamiento de las mismas
WO2004011027A1 (en) * 2002-07-30 2004-02-05 Baxter International Inc. Chimeric multivalent polysaccharide conjugate vaccines
NZ574530A (en) 2002-08-02 2010-12-24 Glaxosmithkline Biolog Sa Vaccine compositions comprising L2 and/or L3 immunotype lipooligosaccharides from lgtB-neisseria minigitidis
GB0220194D0 (en) 2002-08-30 2002-10-09 Chiron Spa Improved vesicles
EP2279746B1 (en) 2002-11-15 2013-10-02 Novartis Vaccines and Diagnostics S.r.l. Surface proteins in neisseria meningitidis
GB0227346D0 (en) 2002-11-22 2002-12-31 Chiron Spa 741
CU23313A1 (es) 2002-11-27 2008-09-25 Inst Finlay Ct De Investigacia Mã0/00todo de obtenciã"n de estructuras cocleares. composiciones vacunales y adyuvantes basados en estructuras cocleares y sus intermediarios
ATE552844T1 (de) 2003-01-30 2012-04-15 Novartis Ag Injizierbarer impfstoff gegen multiple meningokokken-serogruppen
US20040241190A1 (en) * 2003-04-07 2004-12-02 Xenova Research Limited Vaccine preparations
GB0316560D0 (en) * 2003-07-15 2003-08-20 Chiron Srl Vesicle filtration
GB0323103D0 (en) 2003-10-02 2003-11-05 Chiron Srl De-acetylated saccharides
CU23420A1 (es) * 2003-12-30 2009-09-08 Univ De Cambridge Proteoliposomas y sus derivados como adyuvantes inductores de respuesta citotóxica y las formulaciones resultantes
GB0406013D0 (en) 2004-03-17 2004-04-21 Chiron Srl Analysis of saccharide vaccines without interference
GB0408977D0 (en) 2004-04-22 2004-05-26 Chiron Srl Immunising against meningococcal serogroup Y using proteins
GB0411387D0 (en) 2004-05-21 2004-06-23 Chiron Srl Analysis of saccharide length
GB0413868D0 (en) 2004-06-21 2004-07-21 Chiron Srl Dimensional anlaysis of saccharide conjugates
GB0416120D0 (en) 2004-07-19 2004-08-18 Health Prot Agency Stable compositions containing OMV's
GB0424092D0 (en) 2004-10-29 2004-12-01 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
CN101107007B (zh) 2005-01-27 2011-08-17 奥克兰儿童医院及研究中心 对脑膜炎奈瑟球菌所致疾病具有广谱保护作用的gna1870囊泡疫苗
SI1896065T2 (sl) 2005-06-27 2014-12-31 Glaxosmithkline Biologicals S.A. Postopek za pripravo cepiv
GB0524066D0 (en) 2005-11-25 2006-01-04 Chiron Srl 741 ii
GB0605757D0 (en) 2006-03-22 2006-05-03 Chiron Srl Separation of conjugated and unconjugated components
US7943352B2 (en) * 2006-03-29 2011-05-17 Bacoustics, Llc Apparatus and methods for vaccine development using ultrasound technology
EP2007427A4 (en) 2006-04-11 2012-04-04 Yeda Res & Dev IMPROVED VACCINES COMPRISING PEPTIDE MULTIPLE MEDIA DERIVED FROM HSP60
EA200970731A1 (ru) * 2007-02-07 2010-02-26 Сигма-Тау Индустрие Фармасьютике Риуните С.П.А. Рекомбинантные антигены цитомегаловируса человека (hcmv)
EP2886551A3 (en) * 2008-02-21 2015-09-23 Novartis AG Meningococcal fhbp polypeptides
CU20080215A7 (es) 2008-11-19 2012-06-21 Inst Finlay Vacunas unitemporales
CA2772104A1 (en) 2009-08-27 2011-03-03 Novartis Ag Hybrid polypeptides including meningococcal fhbp sequences
MX2012004850A (es) 2009-10-27 2012-05-22 Novartis Ag Polipeptidos fhbp meningococicos modificados.
EP2544712A1 (en) 2010-03-10 2013-01-16 GlaxoSmithKline Biologicals S.A. Immunogenic composition
CU20100083A7 (es) 2010-05-05 2012-06-21 Inst Finlay Tolerogenos adyuvados como vacuna de malaria
CN103189071A (zh) 2010-08-23 2013-07-03 惠氏有限责任公司 脑膜炎萘瑟氏菌rLP2086抗原的稳定制剂
GB201015132D0 (en) 2010-09-10 2010-10-27 Univ Bristol Vaccine composition
WO2012032489A1 (en) 2010-09-10 2012-03-15 Wyeth Llc Non-lipidated variants of neisseria meningitidis orf2086 antigens
CU20110202A7 (es) 2011-11-02 2013-12-27 Inst Finlay Ct De Investigación Producción De Sueros Y Vacunas Composición inmunogénica de polisacáridos planos adyuvados y las formulaciones resultantes
AU2013229063B2 (en) 2012-03-09 2016-10-06 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
EP2689775A1 (en) 2012-07-25 2014-01-29 Instituto Finlay, Centro de Investigacion-Produccion de vacunas y sueros Cochleate with only one mamp
CA2903716C (en) 2013-03-08 2019-04-09 Pfizer Inc. Immunogenic fusion polypeptides
KR102199096B1 (ko) 2013-09-08 2021-01-06 화이자 인코포레이티드 나이세리아 메닌지티디스 조성물 및 그의 방법
AU2015222121B2 (en) 2014-02-28 2018-01-18 Glaxosmithkline Biologicals Sa Modified meningococcal fHbp polypeptides
RU2723045C2 (ru) 2015-02-19 2020-06-08 Пфайзер Инк. Композиции neisseria meningitidis и способы их получения
US10183070B2 (en) 2017-01-31 2019-01-22 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
RU2659948C1 (ru) * 2017-03-14 2018-07-04 Федеральное государственное бюджетное научноеучреждение "Омский аграрный научный центр" (ФГБНУ "Омский АНЦ") Способ получения R-бруцеллёзной сыворотки на кроликах
CN110157767A (zh) * 2019-04-18 2019-08-23 金花企业(集团)股份有限公司 一种转移因子口服溶液生物活性测定方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4271147A (en) * 1980-01-10 1981-06-02 Behringwerke Aktiengesellschaft Process for the isolation of membrane proteins from Neisseria meningitidis and vaccines containing same
US4386066A (en) * 1981-08-20 1983-05-31 Merck & Co., Inc. Immunogenic complex from N. gonorrhoeae
US4451446A (en) * 1982-03-04 1984-05-29 Smithkline-Rit Process for the preparation of polysaccharide-protein complexes from bacterial capsules, obtained products and immunogenic compositions containing them
US4885005A (en) * 1982-11-12 1989-12-05 Baxter International Inc. Surfactant treatment of implantable biological tissue to inhibit calcification
EP0109688A3 (en) * 1982-11-23 1986-12-03 The Wellcome Foundation Limited Improved complexes, processes for obtaining them and formulations containing such complexes
US4505853A (en) * 1983-11-18 1985-03-19 Ortho Pharmaceutical Corporation Enzyme-resistant immunomodulatory peptides
US4547489A (en) * 1984-06-11 1985-10-15 Ortho Pharmaceutical Corporation Conformationally restricted thymopentin-like compounds
US4629723A (en) * 1984-06-27 1986-12-16 Ortho Pharmaceutical Corporation Potent thymopentin analogs
US4601903A (en) * 1985-05-01 1986-07-22 The United States Of America As Represented By The Department Of Health And Human Services Vaccine against Neisseria meningitidis Group B serotype 2 invasive disease
US4786592A (en) * 1986-06-18 1988-11-22 Scripps Clinic And Research Foundation Neisseria gonorrhoeae lectin useful as a vaccine and diagnostic marker and means for producing this lectin
US4838888A (en) * 1987-04-17 1989-06-13 Baxter Travenol Laboratories, Inc. Calcification mitigation of implantable bioprostheses

Also Published As

Publication number Publication date
EP0301992A2 (en) 1989-02-01
AU8134991A (en) 1991-10-31
CA1341199C (en) 2001-03-06
IN167607B (ja) 1990-11-24
EP0301992A3 (en) 1990-02-14
DE3853854D1 (de) 1995-06-29
RU2023448C1 (ru) 1994-11-30
AU5319794A (en) 1994-03-24
US5597572A (en) 1997-01-28
GR3017218T3 (en) 1995-11-30
ATE122893T1 (de) 1995-06-15
EP0301992B1 (en) 1995-05-24
AU2031288A (en) 1989-05-25
ES2074445T3 (es) 1995-09-16
AU615461B2 (en) 1991-10-03
DE3853854T2 (de) 1996-02-08
US5747653A (en) 1998-05-05

Similar Documents

Publication Publication Date Title
JPH01125328A (ja) 髄膜炎菌ワクチン
Andrews et al. Fraction 1 capsular antigen (F1) purification from Yersinia pestis CO92 and from an Escherichia coli recombinant strain and efficacy against lethal plague challenge
Verstreate et al. Outer membrane proteins of Brucella abortus: isolation and characterization
RU2194531C2 (ru) Поливалентные ассоциированные коклюшно-дифтерийно-столбнячно (акдс)-полиомиелитные вакцины
ES2198405T3 (es) Antigenos de superficie de tipo i asociados a staphylococcus epidermis.
Potter et al. Protective capacity of the Pasteurella haemolytica transferrin-binding proteins TbpA and TbpB in cattle
JP2841094B2 (ja) 在郷軍人病ワクチン及びその製造方法
JPS58162531A (ja) 細菌莢膜由来の多糖類−蛋白質複合体の製法、その生成物およびそれを含有する免疫原組成物
CN101730541A (zh) 作为传染性病原体或毒素相关疾病的疫苗佐剂的细胞外基质材料
AU635062B2 (en) Escherichia coli vaccine
Cryz Jr et al. Safety and immunogenicity of a polyvalentKlebsiella capsular polysaccharide vaccine in humans
JPH11507805A (ja) 非細胞性百日咳ワクチンおよびその製造方法
NO175735B (no) Fremgangsmåte ved fremstilling av Pasteurella-vaksine
PT90310B (pt) Processo para a obtencao de preparacoes de adenilato-ciclase
PT680765E (pt) Vacina para estirpe não tipável de haemophilus influenzae.
JP4530317B2 (ja) 減毒化トキシンを含むワクチン製剤
IL30168A (en) Antigen-free vaccine and process for preparing it
Delbaz et al. Biological and immunological evaluation of Neisseria meningitidis serogroup A outer Membrane vesicle as vaccine candidates
Cross Development of an anti-endotoxin vaccine for sepsis
Kushram et al. Production and standardization of combined vaccine against haemorrhagic septicaemia and black quarter
Gilsdorf et al. Reactivity of Haemophilus influenzae type b anti-pili antibodies
Arko et al. Complement-enhanced immunity to infection with Neisseria gonorrhoeae in mice
Afrough et al. A review of research of vaccine against meningococcal disease
AU706213B2 (en) Method for obtaining a vaccine with wide protective range against group B Neisseria Meningitidis, the resulting vaccine, gammaglobulin and transfer factor
Saunders et al. Humoral response of the mouse to Treponema pallidum.

Legal Events

Date Code Title Description
A977 Report on retrieval

Effective date: 20050728

Free format text: JAPANESE INTERMEDIATE CODE: A971007

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Effective date: 20050927

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20051025

R150 Certificate of patent (=grant) or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (prs date is renewal date of database)

Free format text: PAYMENT UNTIL: 20081111

Year of fee payment: 3

FPAY Renewal fee payment (prs date is renewal date of database)

Year of fee payment: 4

Free format text: PAYMENT UNTIL: 20091111

FPAY Renewal fee payment (prs date is renewal date of database)

Year of fee payment: 5

Free format text: PAYMENT UNTIL: 20101111

FPAY Renewal fee payment (prs date is renewal date of database)

Free format text: PAYMENT UNTIL: 20101111

Year of fee payment: 5

FPAY Renewal fee payment (prs date is renewal date of database)

Year of fee payment: 6

Free format text: PAYMENT UNTIL: 20111111

FPAY Renewal fee payment (prs date is renewal date of database)

Year of fee payment: 7

Free format text: PAYMENT UNTIL: 20121111

FPAY Renewal fee payment (prs date is renewal date of database)

Year of fee payment: 8

Free format text: PAYMENT UNTIL: 20131111